Inflammation, peptides and biological therapy

Digestive Diseases

Volumn 27, Issue SUPPL. 1, 2010, Pages 42-47

  Atreya, Raja ^a   Neurath, Markus F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Crohn's disease; Inflammatory bowel disease; Signalling pathways; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; CASPASE 9; CORTICOSTEROID; CYCLOSPORIN A; CYTOCHROME C; CYTOKINE; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MERCAPTOPURINE; MESALAZINE; MESSENGER RNA; METHOTREXATE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BNIP3; SALAZOSULFAPYRIDINE; STAT PROTEIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BIOLOGICAL THERAPY; CD4+ T LYMPHOCYTE; CONFERENCE PAPER; CROHN DISEASE; EFFECTOR CELL; HOMEOSTASIS; HUMAN; IMMUNOPATHOGENESIS; IN VIVO STUDY; INFLAMMATION; INTESTINE BIOPSY; INTESTINE MUCOSA; MACROPHAGE; MITOCHONDRION; PHENOTYPE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN DEGRADATION; T LYMPHOCYTE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; ULCERATIVE COLITIS;

ANIMALS; APOPTOSIS; BIOLOGICAL THERAPY; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-6; PEPTIDES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 77950822015     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000268120     Document Type: Conference Paper

References (50)

1. Strober W, Fuss I, Mannon P: The fundamental basis of inflammatory bowel disease. J Clin Invest 2007;117:514-521.
2. Podolsky DK: Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429.
3. Fiocchi C: Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182-205.
4. Rutgeerts P, Vermeire S, Van Assche G: Biological therapies for inflammatory bowel diseases. Gastroenterology 2009;136:1182-1197.
5. Munkholm P, Langholz E, Hollander D, Thornberg K, Orholm M, Katz KD, Binder V: Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives. Gut 1994; 35: 68-72.
6. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP: Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-241.
7. Shanahan F: Crohn's disease. Gastroenterology 2002; 120: 622-635.
8. Rutgeerts P, Vermeire S, van Assche G: Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136: 1182-1197.
9. Bosani M, Ardizzone S, Porro GB: Biological targeting in the treatment of inflammatory bowel diseases. Biologics 2009; 3: 77-97.
10. Sartor RB: Cytokines in intestinal inflammation: pathophysiologic and clinical considerations. Gastroenterology 1994; 106: 533-539.
11. Neurath MF, Finotto S, Fuss I, Boirivant M, Galle PR, Strober W: Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol 2001; 22: 21-26.
12. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-1132.
13. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C, Strober W: Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157: 1261-1270.
14. Fuss IJ, Marth T, Neurath MF, Pearlstein GR, Jain A, Strober W: Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999; 117: 1078-1088.
15. Stallmach A, Marth T, Weiss B, Wittig BM, Hombach A, Schmidt C, Neurath M, Zeitz M, Zeuzem S, Abken H: An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo. Gut 2004; 53: 339-345.
16. Mannon PJ Fuss IJ Mayer L Elson CO Sandborn WJ Present D Dolin B Goodman N roden C Hornung RL Quezado M Yang Z Neurath MF Salfeld J Veldman GM Schwertschlag U Strober W,Anti-IL-12 Crohn's Disease Study Group: Anti-interleukin-Anti-IL-12 Crohn's Disease Study Group: Anti-interleukin- antibody for active Crohn's disease, N Engl J Med .2004, 351, 2069-2079.
17. Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ: IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004; 202: 96-105.
18. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, Kleinschek MA, Owyang A, Mattson J, Blumenschein W, Murphy E, Sathe M, Cua DJ, Kastelein RA, Rennick D: IL-23 is essential for T cellmediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116: 1310-1316.
19. Schmidt C, Giese T, Ludwig B, Mueller- Molaian I, Marth T, Zeuzem S, Meuer SC, Stallmach A: Expression of interleukin-12- related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 2005; 11: 16-23.
20. Fuss IJ, Becker C, Yang Z, Groden C, Hornung RL, Heller F, Neurath MF, Strober W, Mannon PJ: Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 2006; 12: 9-15.
21. Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ: IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004; 202: 96-105.
22. and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005; 5: 521-531.
23. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240.
24. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238.
25. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT: Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006; 441: 231-234.
26. Mayer L: Current concepts of inflammatory bowel disease: etiology and pathogenesis; in Kirsner JB (ed): Inflammatory Bowel Disease, ed 5. Philadelphia, W.B. Saunders Company, 2000, pp 280-296.
27. Peppelenbosch MP, van Deventer SJ: T cell apoptosis and inflammatory bowel disease. Gut 2004; 53: 1556-1558.
28. Ina K, Binion DG, West GA, Dobrea GM, Fiocchi C: Crohn's disease (CD) mucosal Tcells are resistant to apoptosis. Gastroenterology 1995; 108:A841.
29. Boirivant M, Marini M, Di Felice G, Pronio AM, Montesani C, Tersigni R, Strober W: Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 1999; 116: 557-565.
30. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774-1785.
31. Doering J, Begue B, Lentze MJ, Rieux-Laucat F, Goulet O, Schmitz J, Cerf-Bensussan N, Ruemmele FM: Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease. Gut 2004; 53: 1632-1638.
32. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF: CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 1133-1145.
33. Gross V, Andus T, Caesar I, Roth M, Schölmerich J: Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992; 102: 514-519.
34. Holub MC, Mako E, Devay T, Dank M, Szalai C, Fenyvesi A, Falus A: Increased interleukin-6 levels, interleukin-6 receptor and gp130 expression in peripheral lymphocytes of patients with inflammatory bowel disease. Scand J Gastroenterol Suppl 1998; 228: 47-50.
35. Isaacs KL, Sartor RB, Haskill S: Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992; 103: 1587-1595.
36. Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, Raedler A: Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174-181. (Pubitemid 23308385)
37. Van Kemseke C, Belaiche J, Louis E: Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission. Int J Colorectal Dis 2000; 15: 206-210.
38. Louis E, Belaiche J, van Kemseke C, Franchimont D, de Groote D, Gueenen V, Mary JY: A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease. Eur J Gastroenterol Hepatol 1997; 9: 939-944.
39. Kusugami K, Fukatsu A, Tanimoto M, Shinoda M, Haruta J, Kuroiwa A, Ina K, Kanayama K, Ando T, Matsuura T: Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent. Dig Dis Sci 1995; 40: 949-959.
40. Brown KA, Back SJ, Ruchelli ED, Markowitz J, Mascarenhas M, Verma R, Piccoli DA, Baldassano RN: Lamina propria and circulating interleukin-6 in newly diagnosed pediatric inflammatory bowel disease patients. Am J Gastroenterol 2002; 97: 2603-2608.
41. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schürmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF: Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000; 6: 583-588.
42. Itoh J, de La Motte C, Strong SA, Levine AD, Fiocchi C: Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. Gut 2001; 49: 35-41.
43. Yamamoto M, Yoshizaki K, Kishimoto T, Ito H: IL-6 is required for the development of TH1 cell-mediated murine colitis. J Immunol 2000; 164: 4878-4882.
44. Jostock T, Müllberg J, Özbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF, Rose-John S: Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001; 268: 160-167.
45. Mitsuyama K, Matsumoto S, Rose-John S, Suzuki A, Hara T, Tomiyasu N, Handa K, Tsuruta O, Funabashi H, Scheller J, Toyonaga A, Sata M: STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut 2006; 55: 1263-1269.
46. Ito H: Treatment of Crohn's disease with anti-IL-6 receptor antibody. J Gastroenterol Suppl 2005; 16: 32-34.
47. Lovato P, Brender C, Agnholt J, Kelsen J, Kaltoft K, Svejgaard A, Eriksen KW, Woetmann A, Ødum N: Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. J Biol Chem 2003; 278: 16777-16781.
48. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, Kubo M, Yamashita A, Okabe M, Takeda K, Akira S, Matsumoto S, Toyonaga A, Sata M, Yoshimura A: CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 2001; 193: 471-481.
49. Han X, Sosnowska D, Bonkowski EL, Denson LA: Growth hormone inhibits signal transducer and activator of transcription 3 activation and reduces disease activity in murine colitis. Gastroenterology 2005; 129: 185-203.
50. Mitsuyama K, Sata M, Rose-John S: Interleukin-6 trans-signaling in inflammatory bowel disease. Cytokine Growth Factor Rev 2006; 17: 451-461.